Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR

Thrombosis and Haemostasis

Volumn 81, Issue 5, 1999, Pages 733-738

  Hessner, Martin J ^a   Luhm, Robert A ^b   Pearson, Steven L ^b   Endean, Debra J ^b   Friedman, Kenneth D ^b   Montgomery, Robert R ^b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; PROTHROMBIN;

ALLELE; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; INDIAN; KOREA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RACE; RISK; VEIN THROMBOSIS;

EID: 0032933161     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614563     Document Type: Article

References (39)

1. Kierkegaard A, Incidence of acute deep vein thrombosis in two districts. A phlebographic study. Acta Chir Scand 1981; 246: 267-9.
2. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994; 84: 1031-5.
3. Zoller B, Berntsdotte A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
4. 506). Arterioscler Thromb Vasc Biol 1997; 17: 1662-6.
5. Bertina RM, van Tilburg NH, de Fouw NJ, Haverkate F. Thrombin, a link between coagulation activation and fibrinolysis. Ann N Y Acad Sci 1992; 667: 239-48.
6. Dang OD, Vindigni A, di Cera E. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci USA 1995; 92: 5977-81.
7. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
8. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin G20210A variant: prevalence in a U.K. anticoagulant clinic population. The Br J Haematol 1997; 98: 353-5.
9. Hillarp A, Zoller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothiombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78: 990-2.
10. Dahlbäck B, Carlson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
11. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. New Engl J Med 1994; 330: 517-21.
12. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Rhonde H, van der Velden PA, Reitsma RH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
13. Bertina RM, Reitsma RH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-553.
14. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (APC resistance). Blood 1995; 85: 1505-8.
15. Kang, SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-45.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10: 111-3.
17. van der Put NM, Sttegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, Mariman ECM, den Heyer M, Rozen R, Blom HJ. Mutated methyleneterahydrofolate reductase as a risk factor for spina bifada. Lancet 1995; 346: 1070-1.
18. Kluijtmans LAJ, van den Heuvel LP, Boers GHJ, Frosst P, Stevens EMB, Denheeijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1995; 58: 35-41.
19. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
20. Boers GHJ, Smals AGH, Trijbels JMF, Fowler B, Bakkeren JAJM, Schoonderwalt HC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. New Engl J Med 1985; 313: 709-15.
21. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-17.
22. Heijer MD, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-5.
23. Ocal IT, Sadeghi A, Press RD. Risk of venous thrombosis in carriers of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase. Molecular Diagnosis 1997; 2: 61-8.
24. Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb Haemost 1995; 74: 874-8.
25. Hezard N, Cornillet-Lefebvre P, Gillot L, Potron G, Nguyen P. Multiplex ASA PCR for a simutaneous determination of factor V Leiden gene, G→A 20210 prothrombin gene, and C→T MTHFR gene mutations. Thromb Haemost 1998; 79: 1054-5.
26. Ripoll L, Paulin D, Thomas S, Drouer LO. Multiplex PCR-mediated site directed mutagenesis for one-step determination of factor V Leiden and G20210A transition of the prothrombin gene. Thromb Haemost 1997; 78: 960-1.
27. Gomez E, van der Poel SCPAM, Jansen JH, van der Reijden BA, Lowenberg B. Rapid simutaneous screening of factor V Leiden and G20210A variant by multiplex polymerase chain reaction on whole blood. Blood 1998; 91: 2208-11.
28. Bowen DJ, Bowley S, John M, Collins PW. Factor V Leiden (G1691A), the prothrombin 3′-untranslated region variant (G20210A) and thermolabile methylenetetrahydrofolate reductase (C677T): A single genetic test genotypes at all three loci - Determination of frequencies in the S. Wales population of the UK. Thromb Haemost 1998; 79: 949-54.
29. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997; 78: 1430-3.
30. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
31. Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haematol 1996; 95: 579-86.
32. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. New Engl J Med 1995; 332: 912-7.
33. Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, Attanasio M, Prisco D, Gensini GF, Abbate R. Prevalence of factor V mutation in non-European populations. Thromb Haemost 1997; 77: 329-31.
34. Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnl 1 genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995; 74: 996.
35. Arruda VR, Zuben PM v, Soares MCP, Menezes R, Annichino-Bizzachi JM, Costa FF. Very low incidence of factor VArg506→Gln in the factor V gene among the Amazonian Indians and the Brazilian black population. Thromb Haemost 1996; 75: 860-1.
36. Pottinger P, Sigurdsson F, Berliner N. Detection of factor V Leiden in a nonselected black population. Blood 1996; 78: 2091.
37. Sacchi E, Tagliabue L, Duca F, Mannucci PM, Blanchi A. High frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in northern Italy. Thromb Haemost 1997; 78: 963.
38. Wilcken DE, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol 1996; 16: 878-82.
39. Heijer MD, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Vandenbrouck JP, Rosendaal FR Hyperhomocysteinaemia as a risk factor for deep vein thrombosis. New Engl J Med 1996; 334: 759-62.